Regulatory approval

Published by the Health Service Executive. Approved

Switch maintenance treatment in patients with locally advanced or metastatic NSCLC with EGFR activating mutations and stable disease after first-line chemotherapy

This is written in the approval document.

Reimbursement

CDS

Citation

Erlotinib Therapy, 2021, version number 5, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6938/219_V5_Erlotinib_monotherapy.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	EGFR activating variants	Non-Small Cell Lung Cancer	Erlotinib

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2016-03-25	Health Service Executive	Indication approved for reimbursement.